Sanofi Acquires Vigil Neuroscience for $470 Million, Strengthens Neurology Pipeline

Sanofi has completed the acquisition of Vigil Neuroscience, a neurology-focused biotech, for $470m. The acquisition includes VG-3927, a novel oral TREM2 agonist being evaluated in a phase 2 clinical study for Alzheimer's disease. Sanofi's financial guidance for 2025 is not impacted by the acquisition.

Sanofi has finalized the acquisition of Vigil Neuroscience, Inc., a clinical-stage biotechnology company focused on developing treatments for rare and common neurodegenerative diseases. The acquisition, valued at approximately $470 million, includes the rights to VG-3927, a novel oral TREM2 agonist being evaluated in a phase 2 clinical study for Alzheimer's disease. The acquisition does not impact Sanofi's financial guidance for 2025.

The deal involves Sanofi acquiring all outstanding shares of Vigil Neuroscience for $8 per share, totaling approximately $470 million on a fully diluted basis. Additionally, shareholders of Vigil Neuroscience will receive a deferred cash payment of $2 per share upon the first commercial sale of VG-3927. The acquisition also includes the rights to VG-3927, an orally available small molecule TREM2 agonist being evaluated in a phase 1 clinical trial for Alzheimer's disease in genetically defined subpopulations.

Sanofi's acquisition of Vigil Neuroscience is expected to strengthen its pipeline in neurology, particularly in the area of microglial dysfunction, a key factor in neurodegenerative diseases such as Alzheimer's. The company's lead candidate, VGL101, is a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2, currently in a phase 2 trial for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.

Sanofi's acquisition strategy reflects its commitment to innovation in the field of neurology. The company's acquisition of Vigil Neuroscience aligns with its mission to pursue scientific breakthroughs that improve the lives of millions of people worldwide.

References:
[1] https://www.globenewswire.com/news-release/2025/08/06/3128014/0/fr/Communiqu%C3%A9-de-presse-Sanofi-finalise-l-acquisition-de-Vigil-Neuroscience-Inc.html
[2] https://finance.yahoo.com/quote/VIGL/